Amsterdam, November 10, 2015 - A new cholesterol-lowering vaccine leads to reductions in 'bad' LDL cholesterol in mice and macaques, according to research published in Vaccine. The authors of the study, from the University of New Mexico and the National Institutes of health in the United States, say the vaccine has the potential to be a more powerful treatment than statins alone.
The body produces cholesterol to make vitamin D, some hormones and some of the molecules that help us digest food. Cholesterol is also found in foods. LDL cholesterol is a fat-like substance that circulates in the blood; if there is too much cholesterol, the arteries can become blocked, leading to heart disease and stroke.
According to the CDC, 73.5 million adults in the United States have high LDL cholesterol. Diet and exercise are key to keeping cholesterol down, but millions of people worldwide take statins to lower their cholesterol. Statins have some potentially serious side effects, such as muscle pain, an increased risk of diabetes and cognitive loss.
The new vaccine could provide an alternative to statins, by targeting a protein that controls cholesterol levels in the blood. A single vaccine has been shown to reduce cholesterol levels dramatically in mice and macaques, suggesting it could be an effective treatment in humans.
"One of the most exiting things about this new vaccine is it seems to be much more effective than statins alone," said Dr. Bryce Chackerian, one of the authors of the study from the University of New Mexico.
The new vaccine targets a protein called PCSK9, which regulates the cholesterol in the blood. The protein works by encouraging the body to break down receptors that cholesterol binds to when it's flushed out of the body. People who have a mutation in the protein often suffer from increased risk of heart disease, and people who do not produce the protein have a decreased risk. By targeting this protein, the vaccine can stop it from functioning, lowering the amount of cholesterol in the blood.
The researchers tested the vaccine in mice, which showed a reduced level of LDL cholesterol. They then tested it in a small group of macaques, along with statins, resulting in a dramatic decrease in cholesterol.
"Statins are still the most commonly prescribed medication for cholesterol. Although they are effective in many people, do have side effects and don't work for everyone," said Dr. Alan Remaley, one of the authors of the study from the National Heart, Lung and Blood Institute, National Institutes of Health. "The results of our vaccine were very striking, and suggest it could be a powerful new treatment for high cholesterol."
Several drug companies have been developing high cholesterol treatments that target PCSK9 - for example, Alirocumab and Evolocumab, which the FDA recently approved. Results have been positive, but their treatments, which use monoclonal antibodies, are prohibitively expensive; treatment costs upwards of $10,000 per year.
The new vaccine appears to be even more effective than these monoclonal antibody-based treatments, at a fraction of the cost. The researchers now plan to expand their studies in macaques and find commercial partners to move the technology forward.
Read more about the study on Elsevier Connect.
"A cholesterol-lowering VLP vaccine that targets PCSK9" by Erin Crossey, Marcelo J.A. Amar, Maureen Sampson, Julianne Peabody, John T. Schiller, Bryce Chackerian and Alan T. Remaley (doi: 10.1016/j.vaccine.2015.09.044). The article appears in Vaccine, Volume 33 (October 2015), published by Elsevier.
A copy of the paper is available to credentialed journalists upon request, contact Elsevier's Newsroom at firstname.lastname@example.org or +31 20 4853564.
The official journal of The Edward Jenner Society, the International Society of Vaccines and The Japanese Society for Vaccinology, Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. The journal covers a wide range of vaccine-related topics, including human and veterinary vaccines for infectious and non-infectious diseases, production and manufacturing, and regulatory, societal and legislation aspects.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.